Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
MECHANISMS OF SYNERGISTIC ANTITUMOR EFFECT OF NAPROXEN AND SORAFENIB IN HEPATOCELLULAR CARCINOMA
Download
10527545.pdf
Date
2023-1-23
Author
Akar, Etkin
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
202
views
98
downloads
Cite This
Hepatocellular carcinoma (HCC) is life-threatening cancer that accounts for the second leading cause of cancer-related deaths worldwide. Due to the complexity and heterogeneity of HCC, which leads to resistance to current targeted therapies, combination therapy becomes an important strategy. Since 90% of HCC arises from chronic liver inflammation, HCC drugs combined with non-steroid anti- inflammatory drugs (NSAIDs) are considered an important strategy to increase treatment efficacy. In this study, we aimed to find a synergistic interaction between FDA-approved NSAIDs and HCC drugs and investigate the mechanism behind their synergistic interaction. Among all combinations, Naproxen and Sorafenib were found to be synergistically interacting in HCC. Network reconstruction analysis was performed to investigate the mechanism implicated in this drug combination. Apoptosis pathways were enriched in both Sorafenib and Naproxen networks which were further supported by Annexin V/PI staining, Hoechst staining, and analysis of apoptosis-related proteins in HCC cell lines. Our results pointed out that apoptosis induction could be associated with the down-regulation of the CAPN2 gene and decreasing the activity of PI3K/AKT pathway in HCC.
Subject Keywords
HCC
,
Sorafenib
,
Naproxen
,
Synergy
,
Apoptosis
URI
https://hdl.handle.net/11511/102087
Collections
Graduate School of Natural and Applied Sciences, Thesis
Suggestions
OpenMETU
Core
Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines
Hawash, Mohammed; Kahraman, Deniz Cansen; Ergun, Sezen Guntekin; Cetin-Atalay, Rengul; BAYTAŞ, SULTAN (2021-12-01)
Background Liver cancer is predicted to be the sixth most diagnosed cancer globally and fourth leading cause of cancer deaths. In this study, a series of indole-3-isoxazole-5-carboxamide derivatives were designed, synthesized, and evaluated for their anticancer activities. The chemical structures of these of final compounds and intermediates were characterized by using IR, HRMS, H-1-NMR and C-13-NMR spectroscopy and element analysis. Results The cytotoxic activity was performed against Huh7, MCF7 and HCT116...
In vitro autocrine secretion of inflammatory cytokines in response to drug stress in HCC and LCSC populations
Kalem Yapar, Nisan Ece; Muyan , Mesut; Kahraman, Deniz Cansen; Department of Biology (2022-1-26)
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality. Regardless of its etiology, HCC originates from the constant wound-healing response subsequent to cell death and resulting in a cascade of inflammation. Hence, understanding the importance of inflammatory markers in HCC lies a great importance. A well-known pro-inflammatory cytokine; interleukin-6 has been numerously reported in the sera of HCC patients. This study investigated the effects of IL-6 stimulation in HCC cel...
Molecular Biology of Liver Cancer
Tulin, Ersahin; Öztürk, Mehmet; Atalay, Rengül (2015-01-01)
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer‐related mortality worldwide. Recent advances in the molecular profiling of HCC emphasize its intratumoral heterogeneity and reveal how cellular pathways are altered in favor of tumor progression. Malignant transformation of primary liver cancer is achieved through the acquisition of cancer hallmark capabilities that promote the uncontrolled proliferation of hepatocytes. In this review, the characteristics and acquired capabilities of huma...
Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells
Karaosmanoglu, Oguzhan; Banerjee, Sreeparna; SİVAS, HÜLYA (Springer Science and Business Media LLC, 2018-08-01)
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Complete epithelial to mesenchymal transition (EMT) has long been considered as a crucial step for metastasis initiation. It has, however, become apparent that many carcinoma cells can metastasize without complete loss of epithelial traits or with incomplete gain of mesenchymal traits, i.e., partial EMT. Here, we aimed to determine the similarities and differences between complete and partial EMT through over-expr...
Network-based in silico modeling for drug repurposing and in vitro validation in hepatocellular carcinoma
Nalbat, Esra; Tunçbağ, Nurcan; Cetin-Atalay, Rengul (Orta Doğu Teknik Üniversitesi Enformatik Enstitüsü; 2022-10)
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and a leading cause of death worldwide. The hyperactivated cell survival signaling pathways cause resistance to conventional chemotherapeutics so that targeted therapies could extend patient survival for only a few months. Furthermore, there are limited chemotherapeutics for HCC patients due to impaired liver functions. Thus, it is vital to determine repurposed drugs and drug combinations in HCC treatment.
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
E. Akar, “MECHANISMS OF SYNERGISTIC ANTITUMOR EFFECT OF NAPROXEN AND SORAFENIB IN HEPATOCELLULAR CARCINOMA,” M.S. - Master of Science, Middle East Technical University, 2023.